Lupus & antiphospholipid syndrome
Human papillomavirus (HPV) seroprevalence, cervical HPV prevalence and cervical lesions in systemic lupus erythematosus (SLE) and immunocompetent women
Study context
- Population
- Women aged 18–45 years without history of HPV-related genital lesions or prior HPV vaccination, one hospital in Sao Paulo, Brazilmean age 34.3 and 32.5 years
- Participants
- 122 vs 132
- Exposure
- SLE vs immunocompetent women
- SLEn = 122
- Immunocompetentn = 132reference
- Outcome
- HPV seroprevalence, cervical HPV-DNA detection and HPV-related cervical lesions
Methodological detailssingle-centre, Cervical HPV-DNA by PapilloCheck; Squamous intraepithelial lesions (SIL) by liquid-based cytology; serum antibodies by PsV-Luminex
- Single-centre
- Cervical HPV-DNA by PapilloCheck; SIL by liquid-based cytology; serum antibodies by PsV-Luminex
Main finding
As reported in the abstract
HPV-related cervical lesions (low-grade and high-grade SIL combined)
P = 0.009
Observational data: associations, not effects.
Further findings
At least one cervical HPV type
P = 0.003
Cervical high-risk HPV types · non-significantly higher
P = 0.286
HPV seroprevalence to eight HPV types in the 9vHPV vaccine
P = 0.001
Original publication
Human papillomavirus (HPV) seroprevalence, cervical HPV prevalence and cervical lesions in systemic lupus erythematosus (SLE) and immunocompetent women. Lupus Sci Med. Published 9 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →